10-KPeriod: FY2018

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2018

Filed February 25, 2019For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb's (BMY) 2018 10-K filing highlights a year of strategic focus on its core therapeutic areas, particularly in oncology, immunology, and cardiovascular diseases. The company's performance in 2018 was shaped by its product portfolio, ongoing research and development efforts, and strategic partnerships. Investors should note the company's commitment to innovation, as evidenced by its significant R&D investments, aimed at building a robust pipeline of new therapies. The filing underscores BMY's market position and competitive landscape, detailing its approach to pricing, market access, and government regulation, all of which are critical factors in the pharmaceutical industry. The company emphasizes its robust manufacturing capabilities and quality assurance processes, ensuring the reliable supply of its medicines. While the report focuses on operational and financial performance, it also acknowledges the inherent risks and uncertainties faced by the company, including those related to drug development, regulatory approvals, and market competition.

Financial Highlights

58 data points
Beta

Revenue

$22.56B

71.3% Gross Margin

Net Income

$4.92B

21.8% Net Margin

EPS (Diluted)

$3.01

Total Assets

$34.99B

Cash & Equivalents

$6.91B

Free Cash Flow

$6.12B

Financial Statements
Beta
Revenue$22.56B
Cost of Revenue$6.47B
Gross Profit$16.09B
R&D Expenses$6.33B
SG&A Expenses$4.55B
Operating Expenses$16.59B
Interest Expense$183.00M
Net Income$4.92B
EPS (Basic)$3.01
EPS (Diluted)$3.01
Shares Outstanding (Basic)1.63B
Shares Outstanding (Diluted)1.64B

Key Highlights

  • 1Strong focus on core therapeutic areas: Oncology, Immunology, and Cardiovascular diseases.
  • 2Significant investment in Research and Development (R&D) to fuel pipeline growth and innovation.
  • 3Emphasis on strategic alliances and partnerships to advance drug development and market reach.
  • 4Detailed discussion of competitive landscape, pricing strategies, and market access challenges.
  • 5Commitment to manufacturing excellence and quality assurance for product supply.
  • 6Acknowledgement of regulatory environment and its impact on business operations.
  • 7Inclusion of risk factors pertinent to the pharmaceutical industry, including clinical trial success and patent exclusivity.

Frequently Asked Questions

Bristol-Myers Squibb's primary therapeutic areas of focus are Oncology, Immunology, and Cardiovascular diseases, where the company invests heavily in research and development to bring innovative treatments to patients.

BMY demonstrates a strong commitment to R&D, evidenced by significant investments aimed at advancing its pipeline of novel medicines. This includes exploring new scientific frontiers and pursuing strategic collaborations to enhance innovation.

Key risks include the success of clinical trials, obtaining regulatory approvals for new drugs, patent expirations and exclusivity challenges, intense competition within the pharmaceutical market, pricing pressures, and the impact of government regulations on market access and reimbursement.

While the filing's table of contents lists 'Acquisitions and Divestitures' under Item 1. Business, the provided excerpt does not detail specific transactions. Investors would need to review the full text of Item 1 for details on any significant M&A activities during the reporting period.